Partial
Mostly Aligned
Patient Risk:
Moderate
Summary
Substantial mechanistic and some adverse-event claims align with the provided label sections (Description, Mechanism of Action, Pharmacodynamics, and Adverse Reactions), but multiple clinically contextual and specificity claims are not supported by the supplied label excerpts, and several safety-relevant label areas were not assessed/provided.
Category Scores
Accurate Statements
Nicardipine is a calcium channel blocker (CCB).
11 DESCRIPTION: "calcium ion influx inhibitor (slow channel blocker or calcium channel blocker"
Nicardipine is specifically a dihydropyridine calcium channel blocker.
11 DESCRIPTION: "dihydropyridine derivative"
Nicardipine works by relaxing blood vessels.
12.1 Mechanism of Action + vascular selectivity (inhibits calcium influx into smooth muscle; more selective to vascular smooth muscle than cardiac muscle) and 12.2 decreased systemic vascular resistance.
Nicardipine lowers blood pressure.
12.2 Pharmacodynamics: "significant decreases in systemic vascular resistance" and "resultant decrease in blood pressure"
Nicardipine is used for high blood pressure.
1.1 Hypertension: indicated for short-term treatment of hypertension
As a dihydropyridine, nicardipine mainly affects vascular smooth muscle (blood vessels).
12.1 Mechanism of Action: effects "more selective to vascular smooth muscle than cardiac muscle"
As a dihydropyridine, nicardipine has less effect on the heart’s conduction system.
12.2 Pharmacodynamics: "In general, no detrimental effects on the cardiac conduction system have been seen..."
Common adverse effects of nicardipine reflect vasodilation.
6.1 Clinical Trials Experience: "most were expected consequences of vasodilation"
Nicardipine common adverse effects include headache.
6.1 Clinical Trials Experience table: Headache 21 (15%) vs 2 (2%) on placebo; also narrative noting headache among discontinuation reasons.
Unsupported Statements
Nicardipine is used when clinicians need rapid, controlled blood-pressure lowering in certain acute care settings.
Not supported by the provided label excerpt; 1.1 only states short-term treatment of hypertension when oral therapy is not feasible or not desirable, without mention of rapid controlled lowering or acute care setting.
The specific indications for nicardipine depend on the formulation and country labeling.
No provided label section addresses cross-country or formulation-dependent indication differences.
Non-dihydropyridine calcium channel blockers (such as verapamil and diltiazem) have stronger effects on heart rate and atrioventricular node conduction.
No provided label section compares nicardipine to verapamil/diltiazem or makes this comparative claim.
Nicardipine common adverse effects include flushing.
The provided adverse reaction information does not list flushing as a common adverse event; no provided evidence supports this claim.
Exact risks of nicardipine adverse effects vary by dose and patient factors.
No provided label section explicitly states that adverse-effect risks vary by dose and patient factors.
Nicardipine is available as a generic in many markets.
No provided label section addresses generic availability or market presence.
Availability of nicardipine as a generic depends on formulation.
No provided label section addresses generic availability by formulation.
Availability of nicardipine as a generic depends on local regulatory approvals.
No provided label section addresses generic availability or regulatory approvals.
Contradictions
Important Omissions
No evaluation of contraindications/boxed warnings/warnings and precautions/drug interactions/storage and handling/use in specific populations, because those label sections were not provided in the prompt and the extracted claims did not cover them.
Importance:
High
No label-supported assessment of dosing and administration details (e.g., infusion rates, transition to oral therapy specifics), because no dosage/administration claims were extracted but also the relevant label section (2.1) was not provided.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Mechanism and some adverse-event claims are label-consistent, but several unsupported claims may mislead context/expectations. Additionally, key high-risk FDA label areas (contraindications, boxed warnings, warnings/precautions, interactions, and special populations) were not assessable from the provided excerpts.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Mostly Aligned
Primary Issue
Several extracted claims are not supported by the supplied label excerpts (notably acute-care/rapid lowering context, formulation/country-dependent indications, flushing as common AEs, comparative claims vs verapamil/diltiazem, and generic availability).
Suggested Improvement
Restrict claims to label-supported content from the provided sections (Description, Indications for short-term hypertension, Mechanism of Action/Pharmacodynamics, and the listed adverse events). Remove unsupported statements or provide label sections that explicitly support them; include evaluation of contraindications, boxed warnings, warnings/precautions, interactions, and special populations.